As the Pharmaceutical manufacturing Industry are directly related to benefits of the people's livelihood, the relevant national policy is at the focus of attention, with the biological medicine being classified as a "strategic emerging industry in the Twelfth Five Year Plan". Overall, the development of pharmaceutical manufacturing is good, the indicators have increased greatly. However, affected by the national price policy and the rising cost pressure, the profit margins are falling. Medicine manufacturing industry has resilient demand, strong ability to resist risks, but the industry concentration is low, mergers and acquisitions are imperative. <<